Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Wednesday reported promising preclinical data for its GABAB positive allosteric modulator (PAM) candidate in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF).
Gamma-amino-butyric acid (GABA) is the primary inhibitory neurotransmitter, activating ionotropic (GABAA) and metabotropic (GABAB) receptors. GABAB receptors occur in the peripheral cough neural circuit as well as in the lungs and airways. Targeting these receptors by allosteric modulation can reduce the severity of cough, also known as an antitussive effect.
In preclinical studies on bleomycin (BLM)-exposed animal models, a once-daily administration of the GABAB PAM candidate reduced cough frequency, and increased cough latency. The animal model receiving treatment showed reduced Ashcroft scores, indicating decreased percentage of affected lung tissue. The drug also exhibited a favorable safety profile.
ADXN closed Tuesday at $6.74, up 2.28%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.